A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
Public ClinicalTrials.gov record NCT01647828. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled portion to evaluate the efficacy and safety of OMP-59R5 in combination with nab-paclitaxel and gemcitabine in subjects with previously untreated stage IV pancreatic cancer.
Study identification
- NCT ID
- NCT01647828
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 217 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2012 (Type not available)
- Primary completion
- Apr 2016 (Actual)
- Completion
- Apr 2016 (Actual)
- Last update posted
- Feb 15, 2023
2012 – 2016
United States locations
- U.S. sites
- 26
- U.S. states
- 20
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Western Regional Medical Center, Inc. | Goodyear | Arizona | 85338 | — |
| CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| St Jude Heritage Healthcare Virginia K. Crosson Cancer Center | Fullerton | California | 92835 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| Ronald Reagan UCLA Medical Center, Drug Information Center, Department of Pharmaceutical Services | Los Angeles | California | 90095 | — |
| Torrance Health Association Dba Torrance Memorial Physician Network/Cancer Care Associates | Redondo Beach | California | 90277 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Orlando Health, Inc. | Orlando | Florida | 32806 | — |
| Northside Hospital, Inc. - GCS/Almex | Atlanta | Georgia | 30341 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Allina Health, Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers ofNevada | Las Vegas | Nevada | 89128 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Peggy and Charles Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Bend Memorial Clinic | Bend | Oregon | 97701 | — |
| Greenville Health System, Clinical Research Unit, Institute for Translational Oncology Research | Greenville | South Carolina | 29605 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| South Texas Accelerated Research Thereapeutics, LLC (START) | San Antonio | Texas | 78229 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| University of Wiscons in Hospi tal and Clinics | Madison | Wisconsin | 53792 | — |
| Froedtert Hospital & Medical College of Wisconsin | Milwaukee | Wisconsin | 533226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01647828, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 15, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01647828 live on ClinicalTrials.gov.